Company profile

Albert Bourla
Incorporated in
Fiscal year end

PFE stock data

FINRA relative short interest over last month (20 trading days) ?


7 Nov 19
25 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 12.68B 13.26B 13.12B 13.98B
Net income 7.68B 5.05B 3.88B -393M
Diluted EPS 1.36 0.89 0.68 -0.05
Net profit margin 60.57% 38.04% 29.61% -2.81%
Operating income* 11.13B 4.52B 4.68B -588M
Net change in cash 1B -153M 798M -2.42B
Cash on hand 2.79B 1.78B 1.94B 1.14B
Cost of revenue 2.6B 2.58B 2.43B 3.08B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 53.65B 52.55B 52.82B
Net income 11.15B 21.31B 7.22B 6.96B
Diluted EPS 1.87 3.52 1.17 1.11
Net profit margin 20.79% 40.55% 13.66%
Operating income* 13.17B 13.53B 9.51B 10.14B
Net change in cash -203M -1.25B -1.05B 298M
Cash on hand 1.14B 1.34B 2.6B 3.64B
Cost of revenue 11.25B 11.23B 12.32B 9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

70.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2411 2271 +6.2%
Opened positions 260 106 +145.3%
Closed positions 120 161 -25.5%
Increased positions 980 959 +2.2%
Reduced positions 931 983 -5.3%
13F shares
Current Prev Q Change
Total value 1.49T 1.37T +8.8%
Total shares 3.92B 3.9B +0.7%
Total puts 28.95M 31.33M -7.6%
Total calls 25.65M 25.94M -1.1%
Total put/call ratio 1.1 1.2 -6.6%
Largest owners
Shares Value Change
Vanguard 449.96M $17.63B +1.0%
BLK BlackRock 426.23M $16.7B -0.2%
STT State Street 291.79M $11.43B +0.5%
Wellington Management 193.73M $7.59B +10.9%
Capital World Investors 188.72M $7.39B +13.4%
BAC Bank of America 98.9M $3.88B -4.8%
Geode Capital Management 89.04M $3.48B +1.9%
NTRS Northern Trust 71.18M $2.79B -2.5%
BK Bank Of New York Mellon 59.76M $2.34B +4.9%
N Price T Rowe Associates 59.24M $2.32B -0.4%
Largest transactions
Shares Bought/sold Change
JPM JPMorgan Chase & Co. 51.73M -38.17M -42.5%
Capital World Investors 188.72M +22.23M +13.4%
Wellington Management 193.73M +18.98M +10.9%
Capital International Investors 22.01M -10.14M -31.5%
Renaissance Technologies 13.1M +8.82M +205.9%
DB Deutsche Bank 48.96M +7.17M +17.2%
FHI Federated Hermes 17.68M +6.14M +53.2%
TFC Truist Financial 6.11M +5.18M +559.0%
American Century Companies 19.48M -5.01M -20.5%
BAC Bank of America 98.9M -5M -4.8%
Content analysis ?
8th grade Avg
New words: abandoned, abrocitinib, adjudicated, adjudication, akcea, amlodipine, antisense, attachment, BEACON, bidder, binimetinib, Braftovi, broad, cap, CDI, Chapel, checkpoint, CHMP, clearance, College, confidential, conveyed, copay, copy, creativity, Creek, database, demerger, derecognized, encorafenib, Fabre, FCPA, Glenmark, globulin, heart, Hill, hip, HIPAA, immunosuppression, incidence, infection, Inquiry, introduction, JV, Kit, knee, Likewise, LLP, locked, lymphoproliferative, Mektovi, metabolic, Missouri, NaN, Neulasta, nonsteroidal, OA, Octagam, Panzyga, pegfilgrastim, percent, pharmacovigilance, Pierre, polyneuropathy, PRAC, principle, procedure, qualification, Relpax, Rodino, Russian, Sanford, SC, slightly, superseded, tied, tumor, unamortized, uncertainty, unvested, urgency, Utah, VBP, viii
Removed: annually, Aseptic, avoid, back, biomedical, charitable, convert, deletion, economy, eleven, exon, expedite, extreme, functional, gBRCAm, greatest, Kingdom, men, Modular, pace, Processing, prospective, scaling, social, solvency, substitution, suspected, Venezuelan


Substituted dihydroisoquinolinone compounds
25 Feb 20
Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
Muteins of clotting factor VIII
25 Feb 20
The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
25 Feb 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
SGLT-2 Inhibitors for Treating Metabolic Disorders In Patients with Renal Impairment or Chronic Kidney Disease
20 Feb 20
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Therapeutic Polymeric Nanoparticles Comprising Lipids and Methods of Making and Using Same
20 Feb 20
The present disclosure generally relates to therapeutic nanoparticles.